Business Context and Reporting Period
Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1997
Business Overview: The Company manufactures and distributes natural health and nutritional products through a direct sales marketing program utilizing an independent sales force of Managers and Distributors. Operations are conducted domestically and internationally.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Sales Revenue | $67,825 | $60,113 |
| Operating Income | $6,410 | $5,080 |
| Net Income | $4,010 | $3,276 |
| Diluted EPS | $0.21 | $0.17 |
| Cash from Operations | $11,164 | $11,125 |
| Cash and Equivalents (End) | $30,937 | $22,877 |
| Short-term Debt | $2,376 | $2,788 |
| Inventory | $22,361 | $24,459 |
Note: All dollar amounts in thousands, except per-share data.
Material Changes vs. Prior Period
- Revenue Growth: Sales revenue increased 12.8% ($7.7 million) year-over-year, driven by a 20% increase in domestic Managers since December 1996 and an 18% increase in international sales revenue.
- Profitability: Net income rose 22.4% to $4.0 million. Operating margin improved from 8.45% to 9.45% of sales.
- Cost Structure: Cost of goods sold increased slightly as a percentage of sales (17.78% vs 17.27%) due to international shipping costs. Volume incentives decreased slightly as a percentage of sales (46.30% vs 46.41%) due to the mix of international sales which carry lower incentive rates.
- Balance Sheet: Inventories decreased by approximately $2.1 million due to inventory reduction efforts. Accrued volume incentives increased by $2.3 million reflecting higher sales volume.
Outlook, Risks, and Management Commentary
- Guidance: Management expects cost of goods sold, volume incentives, and SG&A expenses to decrease slightly as a percentage of sales for the remainder of 1997.
- Capital Allocation: The Company purchased $6.8 million (approx. 413,000 shares) of treasury stock in Q1 1997 under a buyback program. Approximately 415,000 shares remain available for purchase.
- Future Investments: The Company plans to establish a new international subsidiary requiring approximately $1.5 million in capitalization over the next 12-18 months. Domestic facility expansion is being evaluated with estimated costs between $6.0 million and $12.0 million; long-term financing may be considered.
- Risks: The Company is subject to foreign currency fluctuations. It is also a defendant in various incidental lawsuits, though management does not expect a material effect on financial position.
Investor Verification Checklist
- Verify the sustainability of the 18% international sales growth and the associated foreign exchange risks.
- Confirm the timeline and funding source for the proposed $6.0M-$12.0M domestic facility expansion.
- Monitor the impact of the new international subsidiary on cash flow and initial capitalization requirements.
- Review the trend in "Volume Incentives" as a percentage of sales to ensure margin stability as the sales force expands.
- Assess the remaining capacity of the stock buyback program and its impact on share count.